For the quarter ending 2026-03-31, ANRO has $276,259K in assets. $32,890K in debts. $263,762K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 263,762 | 176,484 | 137,816 | 147,585 |
| Prepaid expenses and other current assets | 5,364 | 1,234 | 1,632 | 2,261 |
| Total current assets | 269,126 | 177,718 | 139,448 | 149,846 |
| Restricted cash | 500 | 500 | 500 | 500 |
| Property and equipment, net | 2,234 | 1,872 | 2,029 | 2,308 |
| Operating right-of-use asset | 4,061 | 4,261 | 4,459 | 4,653 |
| Other assets | 338 | 338 | 570 | 570 |
| Total assets | 276,259 | 184,689 | 147,006 | 157,877 |
| Accounts payable | 3,369 | 1,878 | 2,059 | 1,671 |
| Accrued expenses and other current liabilities | 7,610 | 8,862 | 6,986 | 6,458 |
| Term loan, current | 2,136 | 585 | - | - |
| Total current liabilities | 13,115 | 11,325 | 9,045 | 8,129 |
| Term loan,non-current | 13,885 | 16,172 | 20,314 | 20,122 |
| Convertible grant agreement | 2,335 | 2,227 | 2,124 | 2,000 |
| Lease liability, long-term | 3,555 | 3,823 | 3,966 | 4,214 |
| Total liabilities | 32,890 | 33,547 | 35,449 | 34,465 |
| Common stock (par value 0.0001), 500,000 shares authorized 35,053 and 31,924 shares issued and outstanding as of march31, 2026 and december31, 2025, respectively | 3 | 3 | 3 | 3 |
| Additionalpaid-incapital | 471,224 | 352,751 | 296,992 | 294,649 |
| Accumulated deficit | -227,871 | -201,634 | -185,452 | -171,271 |
| Accumulated other comprehensive loss | 13 | 22 | 14 | 31 |
| Total stockholders equity | 243,369 | 151,142 | 111,557 | 123,412 |
| Total liabilities and stockholders equity | 276,259 | 184,689 | 147,006 | 157,877 |
Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience, Inc. (ANRO)